Press release
Acute on Chronic Liver Failure Market to Surge as Key Companies Such as Grifols Therapeutics, Versantis AG, Promethera Biosciences, and Others are Exploring the Therapeutics Segment, Assesses DelveInsight
Acute on Chronic Liver Failure Market
The report also offers current Acute on Chronic Liver Failure therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute on Chronic Liver Failure market.
Key Takeaways from the Acute on Chronic Liver Failure Market Report
According to DelveInsight estimates, the Acute on Chronic Liver Failure market size is expected to grow significantly at a considerable CAGR by 2032.
Both hepatic (alcohol-induced liver injury) and extrahepatic (bacterial infections or gastrointestinal hemorrhage) disorders were the most common precipitating disorders for acutely decompensated cirrhosis, with or without ACLF.
Globally, key Acute on Chronic Liver Failure companies such as Promethera Biosciences, Akaza Bioscience, RHEACELL, Tianjin Weikai Bioeng., Ltd., Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., Versantis, GENFIT, and others are developing novel Acute on Chronic Liver Failure drugs that can be available in the Acute on Chronic Liver Failure market in the upcoming years.
Promising Acute on Chronic Liver Failure therapies in the pipeline include Albutein (PE-A 5%), HepaStem, VS-01, and others.
In November 2022, GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients suffering from liver diseases with significant unmet medical needs, announced the highlights of its Pipeline Day events, which reviewed the Company's clinical progress and recent strategic updates.
In September 2022, In a small-time buyout, Genfit SA agreed to acquire Versantis, a Swiss startup, for CHF40 million upfront.
In June 2022, Versantis, a clinical-stage biotechnology company developing novel therapies for orphan and pediatric liver diseases, announced today data demonstrating that both single and repeated intraperitoneal administrations of VS-01 reduced the concentrations of several metabolites in the blood associated with infection-related acute-on-chronic liver failure (ACLF) and multiple organ failure (OF) associated with ACLF.
Discover more about therapies set to grab major Acute on Chronic Liver Failure market share @ Acute on Chronic Liver Failure Market Report- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Acute on Chronic Liver Failure Overview
The term 'acute-on-chronic liver failure (ACLF)' refers to a sudden and potentially fatal worsening of clinical conditions in patients with cirrhosis or chronic liver disease. ACLF is a severe condition with a high morbidity and mortality rate. The European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) Consortium defines ACLF as the failure of one of the six major organ systems. The CLIF-C Organ Failure scale is used to assess the failure of each organ system.
According to NACSELD, the most common organ system failures were brain (36%), circulatory (16%), kidney (13%), and respiratory (9%). 3 The observed 30-day mortality rate gradually increased from 4% in patients with no OF to 27%, 49%, 64%, and 77% in patients with 1, 2, 3, or 4 OFs, respectively.
Learn more about the Acute on Chronic Liver Failure treatment guidelines @ ACLF Guidelines
Acute on Chronic Liver Failure Epidemiological Insights
According to Delveinsight, grade 1 cases accounted for the maximum number of ACLF cases.
DelveInsight's analysis shows that the cases of ACLF show an increasing trend in the forecasted period (2019-2032) in the United States.
The ACLF market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Prevalence of ACLF
Prevalent cases of ACLF by Grades
Organ failures associated with ACLF
Potential precipitating events of ACLF
Download the report to understand which factors are driving Acute on Chronic Liver Failure epidemiology trends @ Acute on Chronic Liver Failure Epidemiological Insights-https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Acute on Chronic Liver Failure Treatment Market
There is currently no specific treatment available for ACLF patients. ACLF management includes etiology-based treatment, controlling and treating complications, providing an artificial liver support system, and performing a liver transplant. Patients with ACLF should preferably be admitted to transplant centers. Organ functions must be closely monitored, and organ-specific treatment is required to prevent multiorgan failure.
The main principles of management in these patients are to support each failing organ and promote hepatic gland recovery. The current treatment consists of detoxification devices, antiviral therapy, and liver transplantation.
To know more about Acute on Chronic Liver Failure treatment options, visit @ ACLF Drugs- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Acute on Chronic Liver Failure Pipeline Therapies
Albutein (PE-A 5%)
HepaStem
VS-01
Acute on Chronic Liver Failure Key Companies
Promethera Biosciences
Akaza Bioscience
RHEACELL
Tianjin Weikai Bioeng., Ltd.
Steminent Biotherapeutics Inc.
Martin Pharmaceuticals, Inc.
GNI Group Ltd.
Versantis
GENFIT
Learn more about the Acute on Chronic Liver Failure therapies in clinical trials @ New Treatment for ACLF- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Acute on Chronic Liver Failure Market Dynamics
Many medical factors influence the global acute liver failure treatment market. Drug-induced acute liver failure is one of the common factors driving the acute liver treatment market. For example, excessive acetaminophen dosage has been identified as the leading cause of acute liver failure in the United States.
As per DelveInsight analysis, Among the EU-5 countries, Germany accounts for the highest market size of the Acute-on-Chronic Liver Failure (ACLF) Market.
In the last five years, the field of ACLF has moved very quickly to meet the current unmet need. The availability of a large volume of published data from the East and West has allowed the initial definitions to be reassessed. Attempts to prevent, mitigate, or reverse the ongoing injury would allow for the restoration of hepatic synthetic functions and the reversal of liver damage. Early predictors of mortality and irreversibility of the condition would pave the way for such patients to receive priority liver transplantation.
Scope of the Acute on Chronic Liver Failure Market Report
Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute on Chronic Liver Failure Companies: Promethera Biosciences, Akaza Bioscience, RHEACELL, Tianjin Weikai Bioeng., Ltd., Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., Versantis, GENFIT (EPA: GNFT), and others
Key Acute on Chronic Liver Failure Therapies: Albutein (PE-A 5%), HepaStem, VS-01, and others
Therapeutic Assessment: Acute on Chronic Liver Failure current marketed and emerging therapies
Acute on Chronic Liver Failure Market Dynamics: Acute on Chronic Liver Failure market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Acute on Chronic Liver Failure Market Access and Reimbursement
Discover more about Acute on Chronic Liver Failure drugs in development @ ACLF Clinical Trials- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Acute on Chronic Liver Failure Market Key Insights
2. Acute on Chronic Liver Failure Market Report Introduction
3. Acute on Chronic Liver Failure Market Overview at a Glance
4. Acute on Chronic Liver Failure Market Executive Summary
5. Disease Background and Overview
6. Acute on Chronic Liver Failure Treatment and Management
7. Acute on Chronic Liver Failure Epidemiology and Patient Population
8. Patient Journey
9. Acute on Chronic Liver Failure Marketed Drugs
10. Acute on Chronic Liver Failure Emerging Drugs
11. Seven Major Acute on Chronic Liver Failure Market Analysis
12. Acute on Chronic Liver Failure Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Acute on Chronic Liver Failure Market Drivers
16. Acute on Chronic Liver Failure Market Barriers
17. Unmet Needs
18. SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Get in touch with our Business executive @ Healthcare Due Diligence Services- https://www.delveinsight.com/consulting?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Info:
Ankit Nigam
Assistant Manager (Marketing & Branding)
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/consulting?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute on Chronic Liver Failure Market to Surge as Key Companies Such as Grifols Therapeutics, Versantis AG, Promethera Biosciences, and Others are Exploring the Therapeutics Segment, Assesses DelveInsight here
News-ID: 2841217 • Views: …
More Releases from DelveInsight Business Research
Global Pharmaceutical Cartridges Market to grow at a CAGR of 7.39% to reach USD …
According to DelveInsight's analysis, The growth of the pharmaceutical cartridges market is largely fueled by the increasing prevalence of chronic diseases that require long-term and consistent medication use. Moreover, the rising trend of self-administered treatments and the growing preference for home-based healthcare are major contributors to market expansion. Technological advancements in drug delivery systems have further supported this growth by enhancing patient convenience, improving dosage precision, and promoting better treatment…
Global Nucleic Acid Amplification Testing Market to grow at a CAGR of 8.13% by 2 …
According to DelveInsight's analysis, The growing demand for Nucleic Acid Amplification Testing (NAAT) is primarily driven by the increasing prevalence of infectious and genetic diseases. Additionally, the rising incidence of cancer and the expanding R&D efforts by major industry players are further fueling market growth. Together, these factors are expected to support a strong upward trajectory for the NAAT market throughout the forecast period from 2025 to 2032.
DelveInsight's "Nucleic Acid…
Global Cardiac Mapping System Market to grow at a CAGR of 8.37% by 2032, Evaluat …
According to DelveInsight's analysis, The growing incidence of cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia, is driving the expansion of the cardiac mapping system market. These systems play a crucial role in the early detection and management of such conditions by providing real-time visualization of the heart's electrical activity, thereby reducing the risk of severe complications like stroke and heart failure. Moreover, the rising adoption of minimally invasive procedures,…
Global Graft Preparation System Market to grow at a CAGR of 4.17% to reach USD 3 …
According to DelveInsight's analysis, The demand for graft preparation systems is experiencing notable growth, primarily driven by the rising incidence of bone disorders and skin-related conditions. Moreover, the increasing number of surgical procedures worldwide, coupled with expanding R&D initiatives and strategic collaborations among leading market players, is further fueling market expansion. Together, these factors are expected to create a strong growth outlook for the graft preparation system market during the…
More Releases for Liver
Rising Liver Disease Cases Drive Growth In Liver Metastases Treatment Market Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Liver Metastases Treatment Market Size By 2025?
The market for treating liver metastases has seen significant growth in the past few years. It is projected to increase from $1.57 billion in 2024 to $1.71 billion in 2025, with a compound annual growth rate (CAGR) of…
LivCare Liver Support
The liver plays a crucial role in maintaining overall well-being, performing essential functions like detoxification, digestion, and metabolism. However, many people overlook the importance of liver health until problems arise. LivCare Liver Support is a premium supplement designed to keep your liver in peak condition. By incorporating this supplement into your daily routine, you can help ensure your liver functions optimally, leading to better overall health.
● Product Name - LivCare…
Liver Cancer Therapeutics Market - Empowering Recovery, Restoring Health: Innova …
Newark, New Castle, USA - new report, titled Liver Cancer Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liver Cancer Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liver Cancer Therapeutics market. The report offers an overview of…
Liver Health Supplements Market Grows Strong as Consumers Adopt Proactive Measur …
Global liver health supplements market was valued at US$ 8.7 Bn in 2021, is growing at an estimated CAGR of 5.8% over the forecast period (2022 - 2030). The liver health supplements market is growing due to the increasing awareness of the importance of liver health and the rise of lifestyle-related liver diseases. The market offers a wide range of supplements that help in improving liver function, supporting liver detoxification,…
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver…
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production…
